TNFRSF17 and Miyoshi myopathy: This hypothesis has been confirmed in a murine BCMA antigen escape model (93) and has paved the way for the MCARH109 trial, a phase I clinical trial to evaluate GPRC5D CAR-T cell therapy in relapsed/refractory MM patients including those who have received prior BCMA-directed therapies (92).